Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have Type 2 Diabetes Mellitus (T2DM) for at least 1 year not treated with insulin~* Have been receiving at least two oral antihyperglycemic medications (OAMs) for at least 3 months prior to screening~* Have Hemoglobin A1c (HbA1c) of 7.0% to 11.0%, inclusive, according to central laboratory at screening~* Body mass index (BMI) ≤35.0 kilogram per square meter (kg/m\^2)~* Inject insulin with a pre-filled insulin pen and perform Self-Monitored Blood Glucose (SMBG)~* Record keeping as required by this protocol~* Women of childbearing potential are not breastfeeding, have a negative pregnancy test at screening, do not plan to become pregnant during the study, have practiced reliable birth control during the study and 2 weeks following the last dose of investigational product~Exclusion Criteria:~* Have used insulin therapy (outside of pregnancy) anytime in the past 2 years, except for short term treatment of acute conditions~* Have been treated with rosiglitazone, pramlintide, glucagon-like peptide-1 (GLP-1) receptor agonist within 3 months prior to screening~* Are using or have used any of the following lipid-lowering medications: niacin preparations as a lipid-lowering medication and/or bile acid sequestrants within 90 days prior to screening~* Local OAM restrictions: have any restrictions for cardiac, renal, and hepatic diseases in the local product regulations~* Are taking, or have taken within 3 months before screening, prescription or over-the-counter medications to promote weight loss~* Have had any episodes of severe hypoglycemia, diabetic ketoacidosis, or hyperosmolar state/coma within 6 months prior to screening~* Have had 1 or more episodes of ketoacidosis or hyperosmolar state/coma in the past 6 months~* Have cardiac disease with functional status that is New York Heart Association Class III or IV~* Have a history of renal transplantation, or are currently receiving renal dialysis or have serum creatinine ≥2.0 milligram per deciliter (mg/dL) (177 micromole per liter \[μmol/L\]). Participants taking metformin should not exceed the creatinine level specified in the local label~* Have obvious clinical signs or symptoms of liver disease (excluding non-alcoholic fatty liver disease \[NAFLD\]), acute or any chronic hepatitis, non alcoholic steatohepatitis (NASH), or elevated liver enzyme measurements~* Have had a blood transfusion or severe blood loss within 3 months prior to screening or have known hemoglobinopathy, hemolytic anemia or sickle cell anemia, or any other traits of hemoglobin abnormalities known to interfere with the measurement of HbA1c~* Have active or untreated cancer, have been in remission from clinically significant cancer(other than basal cell or squamous cell skin cancer) for less than 5 years, or are at increased risk for developing cancer or a recurrence of cancer in the opinion of the investigator~* Have known hypersensitivity or allergy to any of LY2605541 and insulin glargine or their excipients~* Have pre proliferative and proliferative retinopathy, maculopathy requiring treatment or not clinically stable in the last 6 months, or participants with active changes in subjective eye symptoms as determined by the investigator if an eye exam has not been performed in the last 6 months~* Are receiving chronic (lasting longer than 14 consecutive days) systemic glucocorticoid therapy (excluding topical, intranasal, intraocular, and inhaled preparations) or have received such therapy within the 8 weeks immediately preceding screening~* Have fasting triglycerides greater than 400 mg/dL (4.5 mmol/L) at screening as determined by the central laboratory~* Have an irregular sleep/wake cycle (for example, participants who sleep during the day and work during the night) in the investigator's opinion

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Insulin Peglispro (Type: EXPERIMENTAL): Insulin Peglispro administered subcutaneously (SC) once daily for 26 weeks in combination with Oral Antihyperglycemic Medications (OAMs).
- Insulin Glargine (Type: ACTIVE_COMPARATOR): Insulin Glargine administered SC once daily for 26 weeks in combination with OAMs.

Based on this trial design, predict the completion outcome and termination type (if applicable).